Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Assets: 2012-2025

Historic Non-Current Assets for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $76.4 million.

  • Enanta Pharmaceuticals' Non-Current Assets fell 0.53% to $76.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.4 million, marking a year-over-year decrease of 0.53%. This contributed to the annual value of $76.4 million for FY2025, which is 0.53% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Non-Current Assets stood at $76.4 million for Q3 2025, which was down 2.46% from $78.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Non-Current Assets high stood at $129.3 million for Q2 2021, and its period low was $38.2 million during Q4 2023.
  • Over the past 3 years, Enanta Pharmaceuticals' median Non-Current Assets value was $76.4 million (recorded in 2025), while the average stood at $67.9 million.
  • Data for Enanta Pharmaceuticals' Non-Current Assets shows a peak YoY increase of 224.03% (in 2021) and a maximum YoY decrease of 64.30% (in 2021) over the last 5 years.
  • Enanta Pharmaceuticals' Non-Current Assets (Quarterly) stood at $113.6 million in 2021, then crashed by 43.83% to $63.8 million in 2022, then plummeted by 40.16% to $38.2 million in 2023, then skyrocketed by 110.75% to $80.5 million in 2024, then fell by 0.53% to $76.4 million in 2025.
  • Its last three reported values are $76.4 million in Q3 2025, $78.3 million for Q2 2025, and $80.1 million during Q1 2025.